146 related articles for article (PubMed ID: 9839269)
41. [Urogenital complaints: value of systemic estrogen therapy].
Hänggi W; Dörflinger A
Praxis (Bern 1994); 1997 Aug; 86(33):1260-3. PubMed ID: 9381012
[TBL] [Abstract][Full Text] [Related]
42. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
43. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee.
Cardozo L; Bachmann G; McClish D; Fonda D; Birgerson L
Obstet Gynecol; 1998 Oct; 92(4 Pt 2):722-7. PubMed ID: 9764689
[TBL] [Abstract][Full Text] [Related]
44. Managing urogenital atrophy.
Palacios S
Maturitas; 2009 Aug; 63(4):315-8. PubMed ID: 19493638
[TBL] [Abstract][Full Text] [Related]
45. Vaginal ring delivery of hormone replacement therapy--a review.
Dezarnaulds G; Fraser IS
Expert Opin Pharmacother; 2003 Feb; 4(2):201-12. PubMed ID: 12562310
[TBL] [Abstract][Full Text] [Related]
46. Estrogen therapy in older patients with recurrent urinary tract infections: a review.
Rozenberg S; Pastijn A; Gevers R; Murillo D
Int J Fertil Womens Med; 2004; 49(2):71-4. PubMed ID: 15188831
[TBL] [Abstract][Full Text] [Related]
47. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
48. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
50. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?
Del Pup L; Di Francia R; Cavaliere C; Facchini G; Giorda G; De Paoli P; Berretta M
Anticancer Drugs; 2013 Nov; 24(10):989-98. PubMed ID: 24080714
[TBL] [Abstract][Full Text] [Related]
51. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
Simon J; Nachtigall L; Gut R; Lang E; Archer DF; Utian W
Obstet Gynecol; 2008 Nov; 112(5):1053-60. PubMed ID: 18978105
[TBL] [Abstract][Full Text] [Related]
52. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial.
Costantino D; Guaraldi C
Eur Rev Med Pharmacol Sci; 2008; 12(6):411-6. PubMed ID: 19146203
[TBL] [Abstract][Full Text] [Related]
54. The effects of hormones on urinary incontinence in postmenopausal women.
Quinn SD; Domoney C
Climacteric; 2009 Apr; 12(2):106-13. PubMed ID: 19259853
[TBL] [Abstract][Full Text] [Related]
55. Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study.
Farish E; Barnes JF; Rankin M; Hart DM
Climacteric; 2003 Sep; 6(3):211-20. PubMed ID: 14567769
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
Speroff L; Haney AF; Gilbert RD; Ellman H;
Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
[TBL] [Abstract][Full Text] [Related]
57. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol.
Gass MS; Rebar RW; Cuffie-Jackson C; Cedars MI; Lobo RA; Shoupe D; Judd HL; Buyalos RP; Clisham PR
Maturitas; 2004 Oct; 49(2):140-7. PubMed ID: 15474758
[TBL] [Abstract][Full Text] [Related]
58. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
Maturitas; ; . PubMed ID: 15223110
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
